Stay updated with breaking news from Complement Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
Innovate UK has awarded a grant of more than £1 million to a trio of organisations working together on ‘life-changing’ gene therapies.
According to DelveInsight’s analysis, the growth of the gene therapies market in ophthalmology is expected to be mainly driven by the increasing prevalence of eye disease, rise in awareness and access to treatment, increased adoption of enhanced genetic testing and robust pipeline activity for eye disease in the 7MM. LAS VEGAS, April 4, 2024 /PRNewswire/ […]
/PRNewswire/ -- DelveInsight's Gene Therapies in Ophthalmology Market Insights report includes a comprehensive understanding of current treatment practices,...